Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Lin

Showing results (201-210 of 216) with videos related to

Pageof 22
Sort By:
Journal of Medicinal Chemistry|September 30, 2005
5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinaseChunjian Liu, Stephen T Wrobleski, James Lin, et al.
Journal of Medicinal Chemistry|December 13, 2006
2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitorJagabandhu Das, Ping Chen, Derek Norris, et al.
Bioorganic & Medicinal Chemistry Letters|May 10, 2006
Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitorsJagabandhu Das, Joseph A Furch, Chunjian Liu, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2002
Discovery and initial SAR of imidazoquinoxalines as inhibitors of the Src-family kinase p56(Lck)Ping Chen, Derek Norris, Edwin J Iwanowicz, et al.
Journal of Medicinal Chemistry|December 28, 2020
Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2Chunjian Liu, James Lin, Charles Langevine, et al.
National Science Review|August 7, 2023
A common variant in <i>AAK1</i> reduces risk of noise-induced hearing lossQixuan Wang, Xueling Wang, Tao Yang, et al.
Journal of Medicinal Chemistry|August 20, 2004
Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activityPing Chen, Arthur M Doweyko, Derek Norris, et al.
Journal of Medicinal Chemistry|September 12, 2015
Discovery of ((4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carbonyl)(propyl)carbamoyloxy)methyl-2-(4-(phosphonooxy)phenyl)acetate (BMS-751324), a Clinical Prodrug of p38α MAP Kinase InhibitorChunjian Liu, James Lin, John Hynes, et al.
Bioorganic & Medicinal Chemistry Letters|June 14, 2023
Structure-activity relationship study of central pyridine-derived TYK2 JH2 inhibitors: Optimization of the PK profile through C4' and C6 variationsZili Xiao, Michael G Yang, Chunjian Liu, et al.
ACS Medicinal Chemistry Letters|March 21, 2019
Identification of Imidazo[1,2-<i>b</i>]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 InhibitorsChunjian Liu, James Lin, Ryan Moslin, et al.
Pageof 22

Showing results (201-210 of 216) with videos related to

Sort By:
Pageof 22
Journal of Medicinal Chemistry|September 30, 2005
5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinaseChunjian Liu, Stephen T Wrobleski, James Lin, et al.
Journal of Medicinal Chemistry|December 13, 2006
2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitorJagabandhu Das, Ping Chen, Derek Norris, et al.
Bioorganic & Medicinal Chemistry Letters|May 10, 2006
Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitorsJagabandhu Das, Joseph A Furch, Chunjian Liu, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2002
Discovery and initial SAR of imidazoquinoxalines as inhibitors of the Src-family kinase p56(Lck)Ping Chen, Derek Norris, Edwin J Iwanowicz, et al.
Journal of Medicinal Chemistry|December 28, 2020
Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2Chunjian Liu, James Lin, Charles Langevine, et al.
National Science Review|August 7, 2023
A common variant in <i>AAK1</i> reduces risk of noise-induced hearing lossQixuan Wang, Xueling Wang, Tao Yang, et al.
Journal of Medicinal Chemistry|August 20, 2004
Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activityPing Chen, Arthur M Doweyko, Derek Norris, et al.
Journal of Medicinal Chemistry|September 12, 2015
Discovery of ((4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carbonyl)(propyl)carbamoyloxy)methyl-2-(4-(phosphonooxy)phenyl)acetate (BMS-751324), a Clinical Prodrug of p38α MAP Kinase InhibitorChunjian Liu, James Lin, John Hynes, et al.
Bioorganic & Medicinal Chemistry Letters|June 14, 2023
Structure-activity relationship study of central pyridine-derived TYK2 JH2 inhibitors: Optimization of the PK profile through C4' and C6 variationsZili Xiao, Michael G Yang, Chunjian Liu, et al.
ACS Medicinal Chemistry Letters|March 21, 2019
Identification of Imidazo[1,2-<i>b</i>]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 InhibitorsChunjian Liu, James Lin, Ryan Moslin, et al.
Pageof 22